Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What’s In A Name? Hatch And Waxman Stake Claims To Generic Biologics Bill

Executive Summary

Sen. Orrin Hatch, R-Utah, and Rep. Henry Waxman, D-Calif., continue to disagree on how to move toward what could be the next major milestone in the generics industry they essentially created in 1984: generic biologics

You may also be interested in...



Generic Biologics: European-Style Regulation Is The Answer, Big Pharma Says

The Senate Health Committee hearing on developing an approval pathway for generic biologics put the brand-name pharmaceutical industry in the unusual position of advocating that Congress adopt a European-style Rx oversight system

Generic Biologics: European-Style Regulation Is The Answer, Big Pharma Says

The Senate Health Committee hearing on developing an approval pathway for generic biologics put the brand-name pharmaceutical industry in the unusual position of advocating that Congress adopt a European-style Rx oversight system

HATCH/WAXMAN MAY 3 LETTER TO PMA PRESIDENT ENGMAN ON ANDA LEGISLATION

As the Pharmaceutical Mfrs. Assn. Board of Directors convenes, we would like to share with you our view on a number of issues we believe are of mutual interest. While both of our cmtes. have a large number of health programs that must be reauthorized during this Congress, we also plan to address food safety, drug export reform, and patent term restoration/ANDA this year. As you know, our cmtes. have jurisdiction only over the ANDA portion of the patent term restoration/ANDA bill. We are aware that PMA is currently considering a compromise on the patent term restoration/ANDA issue. A decision on the merits of this package should be made by the pharmaceutical companies themselves. In the absence of such a decision, however, we will seriously consider moving this forward in this Congress to resolve this issue. As you consider these questions, please keep in mind that we are jointly committed to bringing about a final resolution of the patent term restoration/ANDA and drug export reform issues. Sincerely, Orrin G. Hatch, Chairman, U.S. Senate Labor & Human Resources Cmte. Henry A. Waxman, Chairman U.S. House of Representatives Subcmte. on Health & Environment

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel